Senseera

Senseera’s novel chromatin-based liquid biopsy (Sadeh et al, Nature Biotechnology, 2021) is a patented, first-in-class biomarker discovery platform. GEM (Genomic Expression Maps) Biomarkers convert a simple blood draw into high-resolution, quantitative, cell-specific gene expression and regulatory data from cell-free DNA—reflecting the activity of tissues and organs across the body. Surpassing traditional cfDNA genomics and methylation techniques, GEM Biomarkers provide a transformative data layer enabling applications such as biomarker discovery, tissue-agnostic MRD detection, therapy response monitoring, dose optimization, disease subtyping, and more. With a growing database of over annotated disease samples and a cohort of more than healthy individuals, Senseera partners with leading pharmaceutical and biotech companies to deliver mechanistic insights with unmatched sensitivity and specificity—accelerating drug development and advancing precision medicine worldwide.